

Protocol for Sampling and Analysis of Finished Medical Marijuana Products and Marijuana-Infused Products for Massachusetts Registered Medical Marijuana Dispensaries

Exhibit 6. Analysis Requirements for Microbiological Contaminants and Mycotoxins in Medical Marijuana Products^a

This document was issued originally by the Department of Public Health (DPH). As part of the transfer of the medical-use of marijuana program on or before December 31, 2018, the Commission adopted this document. We suggest that before you rely on the contents of this document, you check the applicable medical-use marijuana laws, which include include M.G.L. c. 94I and 935 CMR 501.000, as they may provide or clarify the legal requirements related to this document. We also suggest that you periodically check for revisions to this document. Questions with regards to this document may be directed to CannabisCommission@Mass.gov.

Cannabis Material	Total Viable Aerobic Bacteria (CFU/g)	Total Yeast and Mold (CFU/g)	Total Coliforms (CFU/g)	Bile- tolerant Gram- negative Bacteria (CFU/g)	E Coli (pathogenic strains) and Salmonella spp.	Mycotoxins ^c
Unprocessed Materials ^b	10 ⁵	10 ⁴	10	10 ³	Not detected in 1 g	<20 µg of any mycotoxin per kg of material
Processed Materials ^b	10 ⁵	10 ⁴	10	10 ³		
CO ₂ and Solvent-based Extracts	10 ⁴	10 ³	10	10 ²		

Please note that these Protocols are continually evaluated and revised based upon new scientific and industry information.

CFU: colony forming unit



^a Except for mycotoxins, analysis requirements are based on AHP (2013).

^b Unprocessed materials include minimally processed crude cannabis preparations such as inflorescences, accumulated resin glands (kief), and compressed resin glands (hashish). Processed materials include various solid or liquid infused edible preparations, oils, topical preparations, and water-processed resin glands ("bubble hash") (AHP, 2013).

^c Mycotoxins include alfatoxin B1, alfatoxin B2, alfatoxin G1, alfatoxin G2, and Ochratoxin A.